Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Deupirfenidone · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Deupirfenidone | DRUG | size AA Swedish orange capsule |
| Pirfenidone (PFD) | DRUG | size AA Swedish orange capsule |
| Placebo | DRUG | Swedish orange capsule |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
Deupirfenidone is an investigational small molecule being developed for Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease. It is also studied in pharmacokinetic analysis trials. The drug is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
Deupirfenidone is a small molecule being studied for Idiopathic Pulmonary Fibrosis. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not fully characterized in public data. The drug is being evaluated for its efficacy and safety compared to pirfenidone.
Deupirfenidone is being developed by PureTech Health plc, a biopharmaceutical company listed on the London Stock Exchange under the ticker PRTC. The company is conducting clinical trials to evaluate the drug's potential in treating Idiopathic Pulmonary Fibrosis.
Deupirfenidone is in Phase 3 clinical development for Idiopathic Pulmonary Fibrosis. It is an investigational drug, meaning it has not received regulatory approval and is still undergoing clinical trials to assess its safety and efficacy.
Deupirfenidone is being studied in a Phase 3 trial (NCT07284602) comparing it to pirfenidone in adults with Idiopathic Pulmonary Fibrosis, with an enrollment of 1100 participants. A Phase 1 trial (NCT07456800) examining its pharmacokinetics in older healthy subjects has been completed.
Deupirfenidone is not the same as pirfenidone. It is a separate investigational drug being compared to pirfenidone in clinical trials for Idiopathic Pulmonary Fibrosis. The trials are designed to evaluate how Deupirfenidone compares to pirfenidone in terms of efficacy and safety.